Clinical trial · Interventional
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Mature Dendritic Cell Immunotherapy Of Metastatic Melanoma- A Phase I Trial
NCT00017355CI-TRIAL-00012115unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from a patient's white blood cells mixed with tumor antigens may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| filgrastim | Biological | Filgrastim | ALIAS |
| therapeutic autologous dendritic cells | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed metastatic melanoma * HLA-A2-01 phenotype * Measurable disease * No active CNS or hepatic metastases PATIENT CHARACTERISTICS: Age: * 21 and over Performance status: * Karnofsky 80-100% Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * See Disease Characteristics * No viral hepatitis Renal: * Not specified Cardiovascular: * No prior venous thrombosis, angina pectoris, or congestive heart failure * Lactate dehydrogenase less than 2 times normal Pulmonary: * No prior asthma Immunologic: * Intradermal skin test positivity to mumps, Candida, or streptokinase antigen * No known sensitivity to E. coli drug preparations * No prior allergy to influenza vaccine * No active infection * No prior autoimmune disease (e.g., lupus erythematosus, rheumatoid arthritis, or thyroiditis) Other: * HIV negative * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 8 weeks since prior interleukin-2 * At least 4 weeks since prior interferon alfa Chemotherapy: * At least 8 weeks since prior chemotherapy Endocrine therapy: * At least 2 weeks since prior corticosteroids * No concurrent corticosteroids Radiotherapy: * Not specified Surgery: * Not specified Other: * No concurrent immunosuppressive agents * At least 2 weeks since prior immunosuppressive agents
References
Publications (0)
Data not yet available
No reference posted for this study.